Paradigm Biocapital Advisors LP Nuvalent, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 5,269,433 shares of NUVL stock, worth $509 Million. This represents 14.68% of its overall portfolio holdings.
Number of Shares
5,269,433
Previous 5,269,433
-0.0%
Holding current value
$509 Million
Previous $402 Million
13.34%
% of portfolio
14.68%
Previous 18.77%
Shares
8 transactions
Others Institutions Holding NUVL
# of Institutions
211Shares Held
61.3MCall Options Held
35.1KPut Options Held
62.2K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.74 Billion28.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.3MShares$222 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X02.19MShares$211 Million0.09% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.15B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...